Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : Abandoning Insulin Pumps

share with twitter share with LinkedIn share with facebook
share via e-mail
10/05/2017 | 02:28pm CET
By Cara Lombardo 

Johnson & Johnson's Animas Corp. will close and exit the insulin pump business, the company said Thursday, citing increased competition that made selling the pumps unsustainable.

Sales of its Animas Vibe and OneTouch Ping pumps in the U.S. and Canada are discontinued immediately, the company said in a news release. The company said it is still evaluating the timing on exiting markets outside the U.S. and Canada.

J&J said the 90,000 diabetes patients that use Animas products will be offered the option to transfer to a pump from Medtronic PLC. Medtronic has seen demand for its pumps skyrocket after the U.S. Food and Drug and Administration approved two new pumps -- the MiniMed 630G and MiniMed 670G -- within weeks of each other last year.

J&J has been streamlining its business as part of a strategic review. Earlier this year, Chief Executive Alex Gorsky had said the company was evaluating options for its diabetes businesses, including possible sales. The company recorded a $200 million charge in its second quarter, primarily related to the insulin pump business.

J&J said it is continuing to evaluate options for its other diabetes businesses including LifeScan Inc., which makes blood-glucose monitors, and OneTouch products.

"This decision was extremely difficult and comes following the extensive exploration of all other viable options for the Animas business," said Valerie Asbury, general manager of Animas, in prepared remarks.

Animas employs 410 people, but the company didn't say if employees would be laid off.

Write to Cara Lombardo at [email protected]

Stocks mentioned in the article
ChangeLast1st jan.
MEDTRONIC PLC -2.03% 76.55 Delayed Quote.-3.23%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on JOHNSON & JOHNSON
03/23CIPLA : gets tentative approval for gPrezista
03/23JOHNSON & JOHNSON : Biopharmaceutical Industry Marks World TB Day
03/23GSK's two-drug HIV regimen wins European panel approval
03/23OMNICOM : Inside J&J's Effort to Cut Costs and Drive Integration at Ad Firms WPP..
03/23Glaxo in pole position in race for £14bn rival
03/22+10% CAGR GROWTH TO BE ACHIEVED BY D : Know about Digital Marketing Spending Mar..
03/22JOHNSON & JOHNSON : Janssen Announces U.S. FDA Breakthrough Therapy Designation ..
03/22JOHNSON & JOHNSON : Announces Binding Offer from Platinum Equity to Acquire Life..
03/22JOHNSON & JOHNSON : Dominic J. Caruso to Retire as Chief Financial Officer of Jo..
03/22JOHNSON & JOHNSON : to Host Investor Conference Call on First-Quarter Results
More news
News from SeekingAlpha
03/23Alzheon Files To Raise $80 Million In U.S. IPO 
03/23European advisory group backs Novartis biosimilar to J&J's Remicade 
03/23How To Retire At 64 With Only Half A Million 
03/22AstraZeneca Looks To Prove Itself In The Type 2 Diabetes Market 
03/22Rituxan biosimilar captures 80% of British market 
Financials ($)
Sales 2018 81 115 M
EBIT 2018 24 940 M
Net income 2018 19 683 M
Debt 2018 12 439 M
Yield 2018 2,88%
P/E ratio 2018 17,37
P/E ratio 2019 16,30
EV / Sales 2018 4,29x
EV / Sales 2019 3,95x
Capitalization 336 B
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 150 $
Spread / Average Target 20%
EPS Revisions
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-8.83%335 598
NOVARTIS-7.31%207 583
PFIZER0.14%205 314
ROCHE HOLDING LTD.-12.37%196 669
MERCK AND COMPANY-5.08%144 004
AMGEN-2.57%122 085